X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GC1130A (recombinant human heparan N-sulfatase) is an intracerebroventricular (ICV) enzyme replacement therapy candidate. It is under preclinical studies for the treatment of sanfilippo syndrome type A.
Lead Product(s): Recombinant Human Heparan N-sulfatase
Therapeutic Area: Genetic Disease Product Name: GC1130A
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novel Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Alyglo (Immune Globulin Intravenous, Human-stwk) is a liquid solution containing 10% immunoglobulin G (100 mg/mL) for intravenous infusion, manufactured from pooled human plasma from US donors. It is approved by USFDA for adults with Primary Humoral Immunodeficiency (PI).
Lead Product(s): Immune Globulin Intravenous, Human-stwk
Therapeutic Area: Immunology Product Name: Alyglo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2023
Details:
GC1109' contains protective antigen (PA) as its active pharmaceutical ingredients produced by recombinant DNA technology which delivers 2 types of proteins that comprise anthrax toxin. If approved, it" will be the world's first recombinant anthrax vaccine.
Lead Product(s): GC1109
Therapeutic Area: Infections and Infectious Diseases Product Name: GC1109
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2023
Details:
The collaboration combines Immetas’ proprietary platform for modulating innate immune pathways with GC Biopharma’s messenger RNA (mRNA) therapeutic and lipid nanoparticle (LNP) delivery platforms.
Lead Product(s): mRNA Therapeutic
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Immetas Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 12, 2023
Details:
GC1126A is a novel ADAMTS13 mutein designed to evade autoantibodies with an extended half-life, which is investigated for the treatment of thrombotic thrombocytopenic purpura.
Lead Product(s): GC1126A
Therapeutic Area: Rare Diseases and Disorders Product Name: GC1126A
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
The agreement aims to produce cholera vaccines including, Euvichol, an oral cholera vaccine for the prevention of cholera, a disease that is prevalent mainly in the developing countries.
Lead Product(s): Euvichol
Therapeutic Area: Infections and Infectious Diseases Product Name: Euvichol
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: EuBiologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 28, 2023
Details:
GC5107B (Human Immune Globulin) is a liquid solution containing 10% immunoglobulin G for intravenous infusion, manufactured from pooled human plasma from US donors, which is being investigated for the treatment of primary humoral immunodeficiency.
Lead Product(s): Human Immune Globulin
Therapeutic Area: Immunology Product Name: GC5107B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
GCFLU Quadrivalent (prefilled syringes), immunizing against one more strain of influenza virus subtype B in addition to the two strains of subtype A and another strain of subtype B.
Lead Product(s): Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: GCFLU
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
The agreement will bring to GC Biopharma 3 programs, including MarzAA (marzeptacog alfa), an engineered factor VIIa which is ready for Phase 3 clinical stage development.
Lead Product(s): Marzeptacog Alfa
Therapeutic Area: Genetic Disease Product Name: MarzAA
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Catalyst Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 27, 2023
Details:
The results show that varicella incidence cases with complications among Korean children significantly (92%) decreased from 137 per 100,000 persons in 2010 to 11 per 100,000 persons in 2020. I
Lead Product(s): MG1111
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MG1111
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
